TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05046535

Intervention type: BEHAVIORAL
Intervention: Sleep quality and physical activity
Description: Self-reported assessments will be used to measure the following: overall sleep quality, insomnia symptoms, Obstructive sleep apnea.~Physical activity will be measured objectively using the 6MWT, 9HPT, and cardiorespiratory fitness using the VO2 submaximal test on the recumbent stepper.

Intervention type: BEHAVIORAL
Intervention: Sleep quality and physical activity
Description: Self-reported assessments will be used to measure the following: overall sleep quality, insomnia symptoms, Obstructive sleep apnea.~Physical activity will be measured objectively using the 6MWT, 9HPT, and cardiorespiratory fitness using the VO2 submaximal test on the recumbent stepper.

Intervention type: GENETIC
Intervention: Nicotine dependence
Description: DNA sequencing for 20-25 subjects out of the whole sample will be performed. Sanger sequencing to all subjects will also be performed to identify related genes

Intervention type: DIAGNOSTIC_TEST
Intervention: Nicotine and cotinine serum levels
Description: Cotinine serum level which is a major metabolite of nicotine and the preferred biomarker for measuring tobacco use will be measured together with nicotine levels using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Nicotine and cotinine serum levels
Description: Cotinine serum level which is a major metabolite of nicotine and the preferred biomarker for measuring tobacco use will be measured together with nicotine levels using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).

Intervention type: BEHAVIORAL
Intervention: Smoking
Description: Surveys that measure nicotine dependence and smoking behavior
Study: NCT05444400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening
Description: Strengthening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional protocol
Description: Conventional protocol
Study: NCT06649240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: The use of PCSK9 inhibitors is permitted to achieve target LDL-cholesterol levels in participants who did not reach the target with statins ± ezetimibe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCSK9 inhibitor
Description: The use of PCSK9 inhibitors is permitted to achieve target LDL-cholesterol levels in participants who did not reach the target with statins ± ezetimibe.
Study: NCT06648382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-directed psychotherapy program for premenstrual disorders
Description: The intervention consists of receiving 11 videos that are 10-15 minutes in length along with a workbook containing homework exercises. Participants are instructed to watch the videos over the course of two menstrual cycles: the first 6 during the first cycle and the last 5 during the second cycle. Each module focuses on a different skill inspired by cognitive behavioral therapy and dialectical behavior therapy.
Study: NCT06648733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured pharmaceutical discharge management
Description: These patients will receive structured pharmaceutical discharge management from inpatient to outpatient care.
Study: NCT06317142

Intervention type: DRUG
Intervention: Acipimox 250 mg Oral Capsule
Description: A subset of prediabetes individuals (first 10 IFG and 10 IGT subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast,one with lunch and one with snack) and 1x 250mg in the morning of day 4.

Intervention type: DRUG
Intervention: Acipimox 250 mg Oral Capsule
Description: A subset of prediabetes individuals (first 10 IFG and 10 IGT subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast,one with lunch and one with snack) and 1x 250mg in the morning of day 4.
Study: NCT06178731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 3 min rTMS delivery with iTBS to the left DLPFC

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: 3 min rTMS delivery with iTBS to the left DLPFC
Study: NCT05230862

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ladder Supplement
Description: Caffeine 200mg L-Theanine 200mg L-Citrulline 6g Creatine 5g Beta-Alanine 1.6g Phosphatidylserine 100mg
Study: NCT06178731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: 2-15 min VR viewing, 15 min descriptive and imaginal recounting

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality
Description: 2-15 min VR viewing, 15 min descriptive and imaginal recounting
Study: NCT06547424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Description: Neonates with Bell's Stage 2 NEC will be given chondroitin sulfate (20mg/kg/day) mixed with 1-2 ml of milk or formula for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chondroitin sulfate
Description: Neonates with Bell's Stage 2 NEC will be given chondroitin sulfate (20mg/kg/day) mixed with 1-2 ml of milk or formula for 2 days
Study: NCT04917458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 4000 IU Oral Capsule, Liquid Filled
Description: -Vitamin D 25 (OH) or Cholecalciferol 4000 IU capsules, each capsules contain Vitamin D3 tablet @ 1000 IU Patients included into the study will be randomized into two groups and receive placebo (as control group) or cholecalciferol administered orally for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to control group. It would be administrated orally, one capsule once a day for 30 days of study period
Study: NCT04040452

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Continuous ketorolac
Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous ketorolac
Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
Study: NCT05723328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Music Therapy Advocacy Recording Intervention (MTAR)
Description: Music Therapy Advocacy Recording Intervention (MTAR) is a sequence of group music therapy song-writing and recording sessions framed as a mental health awareness project to be shared with the general public.
Study: NCT06177769

Intervention type: DEVICE
Intervention: LMA classic
Description: Airway is secured with LMA clasic

Intervention type: DEVICE
Intervention: LMA Proseal
Description: Airway is secured with LMA proseal

Intervention type: DEVICE
Intervention: I-gel
Description: Airway is secured with I-gel
Study: NCT04892693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Oral Capsule
Description: - Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity
Study: NCT04962724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled Xevinapant 200 mg (Oral Solution)
Description: \[14C\]-Xevinapant 200 mg administered as an oral solution on Day 1 of Part 1, containing approximately 100 microcurie (μCi) \[3.7 megabecquerel (MBq)\] in fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled Xevinapant 100 μg (IV Solution)
Description: 100 μg \[14C\]-xevinapant single dose administered as an IV bolus on Day 1, containing approximately 0.2 μCi \[7.4 kilobecquerel (kBq)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant 200 mg (Oral Solution)
Description: Xevinapant 200 mg administered as an oral solution on Day 1 of Part 2 in fasted conditions
Study: NCT05803096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered Nitrous Oxide
Description: Nitrous oxide administered at concentrations of mild sedation (20-45%) for the duration of prostate biopsy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Oxygen will be administered at 10 Liters/min for the duration of prostate biopsy.
Study: NCT05149352

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU) for depression
Description: TAU for depression will be largely determined by the Dutch multidisciplinary practice guideline on depression (Spijker et al., 2013). This means that patients with CT-related depression will receive good clinical care, e.g. evidence-based psychotherapeutic interventions, such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) combined with/or pharmacotherapy. Therapists who give TAU are not allowed to provide a trauma-focused intervention aimed at CT during the 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU) for depression
Description: TAU for depression will be largely determined by the Dutch multidisciplinary practice guideline on depression (Spijker et al., 2013). This means that patients with CT-related depression will receive good clinical care, e.g. evidence-based psychotherapeutic interventions, such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) combined with/or pharmacotherapy. Therapists who give TAU are not allowed to provide a trauma-focused intervention aimed at CT during the 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused therapy (TFT)
Description: The content of TFT, delivered by another therapist than the therapist that will provide TAU, depends on the type of CT the patient reports. If the patient predominantly reports experiences of abuse, there are often clear memories of this abuse ('target images') present and Eye Movement Desensitization and Reprocessing (EMDR) is recommended as the treatment strategy. If the patient predominantly reports experiences of neglect, memories are often less identifiable, although these experiences can have a big impact on the development of maladaptive schemas. In this case, imagery rescripting (ImRs) is recommended as treatment strategy. If the patient reports both experiences of abuse and neglect, the therapist will discuss with the patient which type of CT has the greatest impact on the current depressive symptoms and starts with the indicated therapy. If indicated, the therapist can switch between EMDR and ImRs after a minimum of 4 sessions.
Study: NCT06255522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fully guided implant placement
Description: Through guided surgery, previously planned and designed based on CBCT study and CAD/CAM scanning, implant placement of Conelog Progressive line implants (Biohorizons Camlog, Iberia) will be performed in maxilla or mandibula in a one stage surgery. Postoperative CBCT in ECO mode (35μSv) will be taken after the implant placement to assess the final position and comparing with the initial digital planning.
Study: NCT05069259

Intervention type: OTHER
Intervention: Stool sample collection
Description: collection for measuring calprotectin levels
Study: NCT05642429

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AV-1959D
Description: Three doses of AV-1959D administered as a sterile suspension via intradermal injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AV-1959D
Description: Three doses of AV-1959D administered as a sterile suspension via intradermal injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AV-1959D
Description: Three doses of AV-1959D administered as a sterile suspension via intradermal injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses of Placebo administered as a sterile suspension via intradermal injection
Study: NCT06420934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drying procedure after surgical handwashing
Description: Participants will dry their hands with one surgical towel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drying procedure after surgical handwashing
Description: Participants will dry their hands with one surgical towel
Study: NCT05230862

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05263076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uterine Transplant
Description: Transplant of a uterus from a live or deceased donor.
Study: NCT04655079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a-tDCS)
Description: tDCS is delivered by a battery-driven constant current stimulator thought a pair of saline soaked surface sponge electrodes. The active electrode (anode) is placed on the scalp over the left dlPFC (F3) according to the 10 to 20 international electroencephalogram coordinates) and the cathode is placed over the right deltoid muscle. During real stimulation a constant current of 2mA (milli Ampere) is applied for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Condition
Description: For the sham condition the electrode placement is the same of active tDCS but the electric current is ramped down 5 seconds after the beginning of the stimulation.
Study: NCT05493982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stanford Vaping Prevention curriculum
Description: Stanford vaping prevention curriculum delivered as a 5-session course administered in a school classroom setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stanford Vaping Prevention curriculum
Description: Stanford vaping prevention curriculum delivered as a 5-session course administered in a school classroom setting.
Study: NCT05535140

Intervention type: OTHER
Intervention: G8 Screening Tool
Description: Determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients \>65y/o who are scheduled with the medical oncology department.
Study: NCT05737576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection; NovoRapid®
Description: HR011408 injection, administered subcutaneously in dose 1. NovoRapid®, administered subcutaneously in dose 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoRapid®；HR011408 injection
Description: NovoRapid®, administered subcutaneously in dose 1. HR011408 injection, administered subcutaneously in dose 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection; NovoRapid®
Description: HR011408 injection, administered subcutaneously in dose 2. NovoRapid®, administered subcutaneously in dose 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoRapid®；HR011408 injection
Description: NovoRapid®, administered subcutaneously in dose 2. HR011408 injection, administered subcutaneously in dose 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection; NovoRapid®
Description: HR011408 injection, administered subcutaneously in dose 3. NovoRapid®, administered subcutaneously in dose 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection; NovoRapid®
Description: NovoRapid®, administered subcutaneously in dose 3. HR011408 injection, administered subcutaneously in dose 3.
Study: NCT04835896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824+paclitaxel
Description: M7824 will be administered intravenously at a dose of 1200 mg every 3 weeks in combination with paclitaxel 80 (or 70) mg/m2 once a week for 3 weeks (each cycle is 4 weeks)
Study: NCT05284305

Intervention type: OTHER
Intervention: Pregnancy
Description: DT with a history of concomitant or subsequent pregnancy.
Study: NCT05844891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER)
Description: TEACH-ER aims to provide primary care management and educational support for families managing childhood asthma throughout the transition from emergency department to home, and includes several core components: 1) brief, pictorial, and health literacy-informed asthma education in the ED, with color- and shape-coded labels provided for home asthma medications; 2) virtual primary care follow-up within 1 week of discharge using in-home telemedicine, featuring provider prompts for guideline-based preventive therapy and home delivery of prescribed medications with pictorial action plans; 3) two additional in-home virtual visits to reinforce teaching, review treatment plans, label medications, and support effective management practices. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices. We anticipate that all three telehealth visits (1 provider visit, 2 educator visits) will be completed within 2 months of enrollment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care (EC)
Description: Similar to children in the TEACH-ER group, participants in the EC group will receive a symptom assessment using NHLBI guidelines, a recommendation for appropriate preventive medications, and asthma education materials given at the time of the ED visit. After baseline and randomization, we will send the child's PCP a symptom report with guideline-based recommendations for preventive care and recommend a follow-up visit with the PCP. We will also give all providers a summary of the current national guidelines. We will provide systematic feedback to the family and child's PCP at intervals that parallel the TEACH-ER group's telemedicine assessments. This feedback will include prompting caregivers to schedule a recommended follow-up appointment with the PCP, and encouraging providers to adhere to the NHLBI guidelines. While participants will not be blinded to their group allocation, they will be told that they are randomly assigned to two different ways of approaching asthma management.
Study: NCT05341206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal gargle
Description: The treatment group receive Herbal gargle 150ml and are instructed to hold the gargle in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
Study: NCT04914052

Intervention type: OTHER
Intervention: Filming facial expressions
Description: Study participants' facial expressions will be videoed by a camera placed in front of the patient's bed during their stay in the post anesthesia care unit.
Study: NCT04981132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience education + Progressive therapeutic exercise training
Description: The education group will have a comprehensive patient education which includes; description, transmission, representation of pain, central sensitization, neuroplasticity, its relation to body systems, psychosocial and emotional factors affecting pain, pain behavior, and lifestyle changes to cope with pain, etc. Plus, the group will have supervised progressive therapeutic exercises via the telerehabilitation method.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive therapeutic exercise training
Description: The exercise group will have supervised progressive therapeutic exercises via the telerehabilitation method.
Study: NCT04646200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Insomnia
Description: CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Wellness
Description: Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
Study: NCT05094193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trocar-site infiltration
Description: 20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 6 mm trocar site)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: bilateral ultrasound-guided TAP block with 20 mL of ropivacaine 0.375% in each side

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trocar site infiltration placebo
Description: 20 mL of normal saline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block placebo
Description: bilateral ultrasound-guided TAP block with 20 mL of normal saline in each side
Study: NCT06016270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hSTC810 400 mg + Paclitaxel
Description: hSTC810 400 mg and paclitaxel 175 mg/m2 will be administered as an intravenous (IV) infusion~Paclitaxel: 175 mg/m2 will be administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hSTC810 800 mg + Paclitaxel
Description: hSTC810 800 mg and paclitaxel 175 mg/m2 will be administered as an IV infusion
Study: NCT05341206

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: The control group receive Normal saline 150ml and are instructed to hold the normal saline in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
Study: NCT06115044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent diurnal nutrition
Description: Calculated daily nutritional requirement given as three equal bolus feeds in daytime with prolonged overnight fast

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous
Description: Calculated daily nutritional requirement given over 24 hours
Study: NCT05056090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients will receive MV in PP
Description: Putting the patient in a prone position